Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ERICOM: Bosentan in Coronary Microvascular Dysfunction
NCT07670091Active, not recruiting
- Sponsor
- Liverpool University Hospitals NHS Foundation Trust
- Start
- Jul 2023
- Primary completion
- Jul 2025
- Countries
- 1
01
Overview
Open-label, single-arm trial of bosentan in Coronary Microvascular Dysfunction (CMD) and microvascular angina (MVA), sponsored by Liverpool University Hospitals NHS Foundation Trust. Primary endpoint: Myocardial Perfusion Reserve Index at 4 weeks. Started Jul 2023; status: active, not recruiting.
02
Drugs
bosentan
03
Conditions
Coronary Microvascular Dysfunction (CMD)microvascular angina (MVA)
Beyond the preview
Go deeper on NCT07670091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07670091.